SUBSEQUENT EVENTS (Additional Information) (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Jul. 28, 2025 |
Jul. 16, 2025 |
Sep. 30, 2025 |
Sep. 30, 2025 |
Jun. 30, 2025 |
Dec. 31, 2024 |
|
| Subsequent Event [Line Items] | ||||||
| Contingent consideration | $ 47,400 | $ 47,400 | ||||
| LGMD FDA Clinical Hold [Member] | ||||||
| Subsequent Event [Line Items] | ||||||
| Contingent consideration | 47,400 | |||||
| Myonexus Therapeutics, Inc. [Member] | LGMD FDA Clinical Hold [Member] | ||||||
| Subsequent Event [Line Items] | ||||||
| Contingent consideration | $ 47,100 | |||||
| Subsequent Event [Member] | ||||||
| Subsequent Event [Line Items] | ||||||
| Reduction in force percentage of companies workforce | 36.00% | |||||
| Subsequent Event [Member] | Arrowhead Agreement [Member] | ||||||
| Subsequent Event [Line Items] | ||||||
| Milestone payment | $ 100,000 | |||||
| Subsequent Event [Member] | Maximum [Member] | ||||||
| Subsequent Event [Line Items] | ||||||
| Restructuring Charges | $ 37,000 | |||||
| Subsequent Event [Member] | Minimum [Member] | ||||||
| Subsequent Event [Line Items] | ||||||
| Restructuring Charges | $ 32,000 |